August 16, 2025

The fibrosis puzzle of systemic sclerosis-associated ILD and the quest for targeted interventions.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Narrative review evaluates fibrosis mechanisms and emerging therapies in systemic sclerosis-associated ILD, suggesting new avenues for treatment.

Significant fibrosis progression impacts morbidity in systemic sclerosis-associated ILD, revealing a critical area for intervention.
The review discusses established therapies like mycophenolate mofetil and novel options, indicating evolving treatment strategies.
Assessment includes the role of T cells and macrophages in the immune-fibrotic crosstalk, highlighting therapeutic implications.
Future research may focus on personalized strategies, particularly the use of epigenetic modulators and cell-based therapies.

Doskaliuk et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Narrative review evaluates fibrosis mechanisms and emerging therapies in systemic sclerosis-associated ILD, suggesting new avenues for treatment.